Secukinumab (AIN457) is a recombinant, highly selective, fully human monoclonal antibody against IL-17A. In vitro treatment of human astrocytes with secukinumab was shown to upregulate the levels of IL-6 and to decrease the levels of proinflammatory molecules [112], thus making it suitable for phase II studies in MS. Here, IL17A is linked to myeloid sarcoma.